Target Name: MIR1255B1
NCBI ID: G100313806
Review Report on MIR1255B1 Target / Biomarker Content of Review Report on MIR1255B1 Target / Biomarker
MIR1255B1
Other Name(s): MicroRNA 1255b-1 | hsa-miR-1255b-5p | MIRN1255B1 | MIR1255B-1 | hsa-mir-1255b-1 | microRNA 1255b-1

MIR1255B1: A Drug Target / Disease Biomarker

MIR1255B1, also known as interleukin-1255B1, is a protein that is expressed in various tissues throughout the body. It is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. MIR1255B1 has been identified as a potential drug target and has been shown to have therapeutic potential in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

MIR1255B1 is a member of the interleukin-12 family, which is a group of cytokines that play a central role in the regulation of immune and inflammatory responses. These cytokines are involved in the recruitment of immune cells to sites of infection or injury, and in the regulation of the cytokine network. MIR1255B1 is expressed in various tissues throughout the body, including the skin, lungs, spleen, and pancreas.

One of the key functions of MIR1255B1 is its ability to stimulate the production of immune cells, such as T cells and natural killer cells. It does this by interacting with the cytokine PD-1, which is a protein that is expressed in various tissues throughout the body. PD-1 is a negative regulator of the immune response, and MIR1255B1 has been shown to bypass this regulation and stimulate the production of immune cells.

In addition to its ability to stimulate the production of immune cells, MIR1255B1 is also involved in the regulation of inflammation. It does this by interacting with the cytokine IL-6, which is a pro-inflammatory cytokine that is involved in the recruitment of immune cells to sites of infection or injury. MIR1255B1 has been shown to regulate the production of IL-6 and to play a role in the regulation of inflammation.

MIR1255B1 has been shown to have therapeutic potential in a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, studies have shown that MIR1255B1 can be used as a potential therapeutic agent for the treatment of skin cancer, due to its ability to stimulate the production of immune cells that can be used to fight off cancer cells.

In addition to its potential as a therapeutic agent, MIR1255B1 has also been identified as a potential drug target. Its ability to stimulate the production of immune cells and its involvement in the regulation of inflammation make it an attractive target for drug development. MIR1255B1 has been shown to interact with a variety of molecules, including PD-1, IL-6, and various signaling pathways. This makes it an attractive target for small molecules and other therapeutic agents that can modulate its activity.

In conclusion, MIR1255B1 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of immune and inflammatory responses. Its ability to stimulate the production of immune cells and its involvement in the regulation of inflammation make it an attractive target for drug development. Further research is needed to fully understand the potential therapeutic potential of MIR1255B1 in the treatment of various diseases.

Protein Name: MicroRNA 1255b-1

The "MIR1255B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1255B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139